The latest progress of GSK's innovative hepatitis B therapies was announced. Recently, GlaxoSmithKline (GSK) announced the interim data analysis results of its Phase II clinical trial of bepirovirsen, a drug for the treatment of chronic hepatitis B, at the European Annual Meeting

2024/06/2314:56:32 science 1415

GSK announces the latest progress in innovative treatments for hepatitis B

The latest progress of GSK's innovative hepatitis B therapies was announced. Recently, GlaxoSmithKline (GSK) announced the interim data analysis results of its Phase II clinical trial of bepirovirsen, a drug for the treatment of chronic hepatitis B, at the European Annual Meeting - DayDayNews

Recently, GlaxoSmithKline (GSK) announced the interim data analysis results of its Phase II clinical trial of its drug bepirovirsen for the treatment of chronic hepatitis B at the European Annual Meeting of the Liver (EASL 2022) , the results show that bepirovirsen has the potential to inhibit hepatitis B surface antigen and the virus, and is expected to functionally cure hepatitis B. The findings will be published in a peer-reviewed journal.


For more hot information, insight analysis, research reports, live lectures... Please pay attention to [Hard Technology]
Welcome to search [Hard Technology] on all major platforms and look for accounts with blue logos!
is here to see, understand and connect with hard technology! We focus on optoelectronic chips, artificial intelligence , aerospace, new energy, smart cars, biomedicine , science and technology finance and other industries, and rely on the unique scientific and technological intelligence data owned by the scientific and technological innovation intelligence SaaS service provider Smart Bud. Advantages, work with readers to see technology trends, understand hard technology industries, and connect to the innovative future. "Hard Technology" is produced by the Smart Bud Innovation Research Center.

science Category Latest News